OTCBB:GTBP

Gt Biopharma Stock Insider Trading

Healthcare > Biotechnology

Buy GTBP

*Your capital is at risk

$0.439

-0.0279 (-5.97%)

At Close: Jun 03, 2026

GT Biopharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 10.86M and sold 660K GTBP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	10.86M shares
● Sell	660K shares
94% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Mun-gavin David C. Director	Director	31 250 Value: $41.6K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Breen Michael Martin CEO And Director	CEO / President	100 000 Value: $133.0K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Urban Alan Louis Chief Financial Officer	C-Suite Officer	50 000 Value: $66.5K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Casamento Charles J Director	Director	62 500 Value: $83.1K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Kramer Hilary Director	Director	31 250 Value: $41.6K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Kramer Hilary Director	Director	31 250 Value: $41.6K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Casamento Charles J Director	Director	62 500 Value: $83.1K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Urban Alan Louis Chief Financial Officer	C-Suite Officer	50 000 Value: $66.5K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Breen Michael Martin CEO And Director	CEO / President	100 000 Value: $133.0K
Sep 04, 2025 Buy	Option to purchase Common Stock A-Award	Mun-gavin David C. Director	Director	31 250 Value: $41.6K
Jun 10, 2025 Buy	Common Stock J-Other	Mun-gavin David C.	Director	0 Value: $0
Jun 10, 2025 Buy	Common Stock J-Other	Mun-gavin David C.	Director	0 Value: $0
May 08, 2025 Buy	Common Stock J-Other	Ritter Andrew J	Director	0 Value: $0
May 08, 2025 Buy	Common Stock J-Other	Ritter Andrew J	Director	0 Value: $0
May 07, 2025 Buy	Common Stock J-Other	Kramer Hilary	Director	0 Value: $0
May 07, 2025 Buy	Common Stock J-Other	Kramer Hilary	Director	0 Value: $0
Oct 17, 2024 Buy	Option to purchase Common Stock A-Award	Urban Alan Louis Chief Financial Officer	C-Suite Officer	23 335 Value: $49.2K
Oct 17, 2024 Buy	Option to purchase Common Stock A-Award	Urban Alan Louis Chief Financial Officer	C-Suite Officer	23 335 Value: $49.2K
Jun 03, 2024 Buy	Common Stock J-Other	Urban Alan Louis Officer	Officer	0 Value: $0
Jun 03, 2024 Buy	Common Stock J-Other	Urban Alan Louis Officer	Officer	0 Value: $0
Aug 11, 2023 Buy	Common Stock A-Award	Breen Michael Martin Executive Chairman/interim CEO	CEO / President	200 000 Value: $57.4K
Aug 11, 2023 Buy	Common Stock J-Other	Ohri Manu CFO & Secretary	C-Suite Officer	200 000 Value: $57.4K
Aug 11, 2023 Buy	Common Stock A-Award	Ohri Manu CFO & Secretary	C-Suite Officer	200 000 Value: $57.4K
Aug 11, 2023 Sell	Common Stock J-Other	Ohri Manu CFO & Secretary	C-Suite Officer	200 000 Value: $57.4K
Aug 11, 2023 Sell	Common Stock J-Other	Ohri Manu CFO & Secretary	C-Suite Officer	200 000 Value: $57.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GT BIOPHARMA, INC.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed ...

Read Full Profile Here